Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

被引:4539
|
作者
Jaakkola, P
Mole, DR
Tian, YM
Wilson, MI
Gielbert, J
Gaskell, SJ
von Kriegsheim, A
Hebestreit, HF
Mukherji, M
Schofield, CJ
Maxwell, PH
Pugh, CW
Ratcliffe, PJ
机构
[1] Univ Oxford, Oxford OX3 7BN, England
[2] Univ Manchester, Inst Sci & Technol, Dept Chem, Michael Barber Ctr Mass Spectrometry, Manchester M60 1QD, Lancs, England
[3] Univ Oxford, Glycobiol Inst, Oxford OX1 3QU, England
[4] Univ Oxford, Dyson Perrins Lab, Oxford Ctr Mol Sci, Oxford OX1 3QY, England
关键词
D O I
10.1126/science.1059796
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Hypoxia-inducible factor (HIF) is a transcriptional complex that plays a central role in the regulation of gene expression by oxygen. In oxygenated and iron replete cells, HIF-alpha subunits are rapidly destroyed by a mechanism that involves ubiquitylation by the von Hippel-Lindau tumor suppressor (pVHL) E3 Ligase complex. This process is suppressed by hypoxia and iron chelation, allowing transcriptional activation. Here we show that the interaction between human pVHL and a specific domain of the HIF-1 alpha subunit is regulated through hydroxylation of a proline residue (HIF-1 alpha P564) by an enzyme we have termed HIF-alpha prolyl-hydroxylase (HIF-PH). An absolute requirement for dioxygen as a cosubstrate and iron as cofactor suggests that HIF-PH functions directly as a cellular oxygen sensor.
引用
收藏
页码:468 / 472
页数:5
相关论文
共 49 条
  • [21] Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1α interactions
    Knauth, K
    Bex, C
    Jemth, P
    Buchberger, A
    ONCOGENE, 2006, 25 (03) : 370 - 377
  • [22] Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2α gain-of-function mutation
    Formenti, Federico
    Beer, Philip A.
    Croft, Quentin P. P.
    Dorrington, Keith L.
    Gale, Daniel P.
    Lappin, Terence R. J.
    Lucas, Guy S.
    Maher, Eamonn R.
    Maxwell, Patrick H.
    McMullin, Mary F.
    O'Connor, David F.
    Percy, Melanie J.
    Pugh, Christopher W.
    Ratcliffe, Peter J.
    Smith, Thomas G.
    Talbot, Nick P.
    Robbins, Peter A.
    FASEB JOURNAL, 2011, 25 (06): : 2001 - 2011
  • [23] Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel-Lindau Disease
    Albinana, Virginia
    Gallardo-Vara, Eunate
    de Rojas-P, Isabel
    Recio-Poveda, Lucia
    Aguado, Tania
    Canto-Cano, Ana
    Aguirre, Daniel T.
    Serra, Marcelo M.
    Gonzalez-Peramato, Pilar
    Martinez-Pineiro, Luis
    Cuesta, Angel M.
    Botella, Luisa Maria
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) : 1 - 30
  • [24] Role of hypoxia-inducible factor (HIF)-1α-versus HIF-2α in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-1, or loss of von Hippel-Lindau function:: Implications for targeting the HIF pathway
    Carroll, Veronica A.
    Ashcroft, Margaret
    CANCER RESEARCH, 2006, 66 (12) : 6264 - 6270
  • [25] Von Hippel-Lindau (VHL) Protein Antagonist VH298 Improves Wound Healing in Streptozotocin-Induced Hyperglycaemic Rats by Activating Hypoxia-Inducible Factor- (HIF-) 1 Signalling
    Qiu, Shuo
    Jia, Yachao
    Sun, Yunchu
    Han, Pei
    Xu, Jia
    Wen, Gen
    Chai, Yimin
    JOURNAL OF DIABETES RESEARCH, 2019, 2019
  • [26] The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease
    Cuesta, A. M.
    Albinana, V
    Gallardo-Vara, E.
    Recio-Poveda, L.
    de Rojas-P, I
    Gomez de Las Heras, K. Villar
    Aguirre, D. T.
    Botella, L. M.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [27] The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease
    A. M. Cuesta
    V. Albiñana
    E. Gallardo-Vara
    L. Recio-Poveda
    I. de Rojas-P
    K. Villar Gómez de Las Heras
    D. T. Aguirre
    L. M. Botella
    Scientific Reports, 9
  • [28] Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease-associated renal cell carcinoma.
    Jonasch, Eric
    Donskov, Frede
    Iliopoulos, Othon
    Rathmell, Wendy Kimryn
    Narayan, Vivek
    Maughan, Benjamin Louis
    Oudard, Stephane
    Else, Tobias
    Maranchie, Jodi K.
    Welsh, Sarah J.
    Thamake, Sanjay
    Park, Eric Kristopher
    Zojwalla, Naseem J.
    Perini, Rodolfo F.
    Linehan, W. Marston
    Srinivasan, Ramaprasad
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] The von Hippel-Lindau (VHL) Tumor-suppressor Gene is Down-regulated by Selenium Deficiency in Caco-2 Cells and Rat Colon Mucosa
    Eric Uthus
    Adrienne Begaye
    Sharon Ross
    Huawei Zeng
    Biological Trace Element Research, 2011, 142 : 223 - 231
  • [30] The von Hippel-Lindau (VHL) Tumor-suppressor Gene is Down-regulated by Selenium Deficiency in Caco-2 Cells and Rat Colon Mucosa
    Uthus, Eric
    Begaye, Adrienne
    Ross, Sharon
    Zeng, Huawei
    BIOLOGICAL TRACE ELEMENT RESEARCH, 2011, 142 (02) : 223 - 231